NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® ...
Lead Author: Enrique Alvarez, MD, University of Colorado, Aurora, CO Following the presentation, the data will be available on the Publications page, located within ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results